Madrigal Pharmaceuticals (MDGL) Net Cash Flow (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Net Cash Flow data on file, last reported at $27.1 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 67.61% year-over-year to $27.1 million in Q1 2026; TTM through Mar 2026 was $42.2 million, a 109.73% increase from a year earlier, with the FY2025 full-year figure at $98.8 million, up 1834.78% from the prior year.
• Net Cash Flow for Q1 2026 stood at $27.1 million, up from -$96.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for MDGL reached as high as $522.6 million in Q1 2024 and fell as low as -$261.9 million in Q3 2024.
• Historically, Net Cash Flow has averaged $11.4 million across 5 years, with a median of $6.0 million in 2022.
• Across the five-year window, Net Cash Flow soared 2209.33% in 2022 and slumped 3729.49% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at $272.2 million in 2022, then sank by 86.09% to $37.9 million in 2023, then tumbled by 450.41% to -$132.7 million in 2024, then increased by 26.94% to -$96.9 million in 2025, then surged by 127.94% to $27.1 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $27.1 million in Q1 2026, -$96.9 million in Q4 2025, and $109.5 million in Q3 2025.